SENSOTECH HEALTH GROUP LLC

Capabilities

SensoTech Health Group LLC is a biotech startup pioneering AI-powered electronic nose (ENose) technology for non-invasive disease diagnostics. Founded in 2025 in Rolla, MO, the company focuses on early lung cancer detection via breath analysis, identifying disease-specific VOCs. Collaborating with leading institutions, oncologists, and pulmonologists, SensoTech aims to commercialize a cost-effective alternative to CT scans and biopsies. The ENose system integrates MOS gas sensors, AI-driven pattern recognition, and cloud-based analytics for real-time, accurate diagnostics. SensoTech’s strategy includes clinical trials and FDA approval (2025-2026), pilot production (2026-2027), and global expansion (2027-2028). Revenue streams include device sales, AI diagnostic subscriptions, and NIH SBIR grants. SensoTech pursues FDA 510(k) clearance and HIPAA compliance, with future applications in gastrointestinal, metabolic, and neurological diseases, setting a new standard in diagnostics.